S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
LON:ERGO

Ergomed (ERGO) Share Forecast, Price & News

GBX 1,004
-14.00 (-1.38%)
(As of 04:35 PM ET)
Compare
Today's Range
1,004
▼
1,048
50-Day Range
977
▼
1,086
52-Week Range
910
▼
1,380
Volume
53,002 shs
Average Volume
139,464 shs
Market Capitalization
£506.02 million
P/E Ratio
3,585.71
Dividend Yield
N/A
Price Target
GBX 1,525
ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines

ERGO stock logo

About Ergomed (LON:ERGO) Stock

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Receive ERGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter.

ERGO Stock News Headlines

May 10, 2023 | americanbankingnews.com
Ergomed (LON:ERGO) Stock Price Passes Above Fifty Day Moving Average of $1,046.73
May 8, 2023 | finance.yahoo.com
Is Weakness In Ergomed plc (LON:ERGO) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
May 30, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
April 12, 2023 | msn.com
I just bought these beaten-up growth stocks for my ISA
April 8, 2023 | finance.yahoo.com
Investing in Ergomed (LON:ERGO) five years ago would have delivered you a 406% gain
March 24, 2023 | americanbankingnews.com
Shore Capital Reiterates Hold Rating for Ergomed (LON:ERGO)
March 23, 2023 | americanbankingnews.com
Ergomed (LON:ERGO) Rating Reiterated by Berenberg Bank
March 22, 2023 | finance.yahoo.com
Ergomed Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
May 30, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
March 20, 2023 | finance.yahoo.com
Estimating The Fair Value Of Ergomed plc (LON:ERGO)
February 26, 2023 | msn.com
Just released: the 3 best small-cap stocks to buy now [PREMIUM PICKS]
February 21, 2023 | marketwatch.com
Pharmacovigilance Outsourcing Market 2023 Size, Share, Growth, Analysis, Trends and Forecast to 2028
February 20, 2023 | finance.yahoo.com
If EPS Growth Is Important To You, Ergomed (LON:ERGO) Presents An Opportunity
January 25, 2023 | morningstar.com
EasyJet Shares Jump After Upbeat 1Q, Strong Outlook
January 25, 2023 | marketwatch.com
Ergomed Sees 2022 Adjusted Earnings Meeting Market Views; Names New CFO
January 23, 2023 | finance.yahoo.com
When Should You Buy Ergomed plc (LON:ERGO)?
December 28, 2022 | uk.finance.yahoo.com
Ergomed plc (ERGO.L)
November 28, 2022 | finance.yahoo.com
Are Robust Financials Driving The Recent Rally In Ergomed plc's (LON:ERGO) Stock?
November 21, 2022 | markets.businessinsider.com
Ergomed (ERGO): Two key management changes
November 17, 2022 | marketwatch.com
Ergomed Names Jonathan Curtain as Deputy CFO
October 30, 2022 | finance.yahoo.com
The 9.0% return this week takes Ergomed's (LON:ERGO) shareholders five-year gains to 484%
October 10, 2022 | finance.yahoo.com
Is There An Opportunity With Ergomed plc's (LON:ERGO) 29% Undervaluation?
October 4, 2022 | markets.businessinsider.com
Ergomed (ERGO): Poised for a strong FY22
September 26, 2022 | yahoo.com
Global Rare Disease Genetic Testing Market to Reach $2.52 Billion by 2030
September 16, 2022 | yahoo.com
Global Rare Disease Genetic Testing Market Report 2022: Government & Regulatory Support for Rare Disease Diagnosis to Drive Growth
September 13, 2022 | finance.yahoo.com
Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?
September 8, 2022 | markets.businessinsider.com
Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations
See More Headlines
Receive ERGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter.

ERGO Company Calendar

Last Earnings
9/18/2017
Today
5/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:ERGO
CUSIP
N/A
CIK
N/A
Web
www.ergomedplc.com
Phone
+44-1483-503205
Fax
N/A
Employees
1,371
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,525
High Stock Price Forecast
GBX 1,600
Low Stock Price Forecast
GBX 1,450
Forecasted Upside/Downside
+48.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX 0.28
Trailing P/E Ratio
3,660.71
Forward P/E Ratio
20.66
P/E Growth
N/A
Net Income
£14.98 million
Net Margins
10.31%
Pretax Margin
N/A
Return on Equity
19.72%
Return on Assets
10.91%

Debt

Debt-to-Equity Ratio
3.43
Current Ratio
1.50
Quick Ratio
1.22

Sales & Book Value

Annual Sales
£145.26 million
Price / Sales
3.56
Cash Flow
GBX 18.75 per share
Price / Cash Flow
54.67
Book Value
GBX 168 per share
Price / Book
6.10

Miscellaneous

Outstanding Shares
50,400,000
Free Float
N/A
Market Cap
£516.60 million
Optionable
Not Optionable
Beta
0.83

Key Executives

  • Dr. Miroslav Reljanovic (Age 64)
    Founder & Exec. Chairman
    Comp: $641.1k
  • Mr. Richard T. Barfield (Age 65)
    CFO & Exec. Director
    Comp: $438.78k
  • Mr. Michael William Spiteri (Age 62)
    Chief Transformation & Technology Officer
    Comp: $60k
  • Mr. Shaun Hopgood
    Chief Information Officer
  • Dr. Michael Forstner
    Head of Risk Management & Pharmacoepidemiology
  • Ms. Sally Amanuel
    Pres of PrimeVigilance
  • Dr. Gordana Tonkovic
    Pres of Clinical Research
  • Ms. Ronel Steyn
    Sr. VP of Global Devel.
  • Keith Byrne
    Sr. Vice-Pres of Capital Markets & Strategy
  • Jonathan Curtain
    Deputy CFO

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ERGO Stock - Frequently Asked Questions

Should I buy or sell Ergomed stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ergomed in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ERGO shares.
View ERGO analyst ratings or view top-rated stocks.

What is Ergomed's stock price forecast for 2023?

3 analysts have issued 12-month target prices for Ergomed's shares. Their ERGO share price forecasts range from GBX 1,450 to GBX 1,600. On average, they predict the company's stock price to reach GBX 1,525 in the next year. This suggests a possible upside of 48.8% from the stock's current price.
View analysts price targets for ERGO or view top-rated stocks among Wall Street analysts.

How have ERGO shares performed in 2023?

Ergomed's stock was trading at GBX 1,272 at the start of the year. Since then, ERGO shares have decreased by 19.4% and is now trading at GBX 1,025.
View the best growth stocks for 2023 here.

How were Ergomed's earnings last quarter?

Ergomed plc (LON:ERGO) posted its quarterly earnings results on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The business had revenue of $22.91 million for the quarter. Ergomed had a trailing twelve-month return on equity of 19.72% and a net margin of 10.31%.

What other stocks do shareholders of Ergomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), Axsome Therapeutics (AXSM), FuelCell Energy (FCEL), NIO (NIO), Science Applications International (SAIC), Northern Dynasty Minerals (NAK), Tilray (TLRY), Agilent Technologies (A) and American Express (AXP).

What is Ergomed's stock symbol?

Ergomed trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."

How do I buy shares of Ergomed?

Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Ergomed's stock price today?

One share of ERGO stock can currently be purchased for approximately GBX 1,025.

How much money does Ergomed make?

Ergomed (LON:ERGO) has a market capitalization of £516.60 million and generates £145.26 million in revenue each year. The company earns £14.98 million in net income (profit) each year or GBX 0.28 on an earnings per share basis.

How many employees does Ergomed have?

The company employs 1,371 workers across the globe.

How can I contact Ergomed?

Ergomed's mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The official website for the company is www.ergomedplc.com. The company can be reached via phone at +44-1483-503205.

This page (LON:ERGO) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -